ANTIBODY COCKTAIL : New medication for Covid-19 treatment
The Antibody Cocktail (also known as Regeneron or Regen-Cov) is a novel treatment for COVID19 infection. It has been approved in many countries including USA, India, Japan, England and Thailand. In July 2021, The Thai FDA has issued an emergency use authorization (EUA) for the antibody cocktail (casirivimab and imdevimab) to be administered for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who have certain chronic medical conditions. The antibody cocktail of casirivimab and imdevimab significantly reduced the risk of hospitalisation or death by 70% according to the REGEN-COV™ Phase III trial. This could be a specific and novel treatment to prevent COVID19 pneumonia progression and death. INDEX: What is “Antibody Cocktail” What is the difference between “Antibody Cocktail”, favipiravir and COVID-19 vaccines? How does the Antibody Cocktail work? Who Is Eligible to Receive Anti-SARS-CoV-2 Monoclonal Antibodies? Difference between convalescent plasma and Antibody Cocktail Antibody Cocktail Efficacy Contraindication, precaution and side effects of Antibody Cocktail Summary What is “Antibody Cocktail” Antibody Cocktail or “REGEN-COV” is a cocktail of two monoclonal antibodies (casirivimab with imdevimab) that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. The antibodies bind to the critical receptor
